ESC 365 - Understanding new PCSK9 outcome data: from the LDL-C hypothesis to LDL-c causality.

ESC Premium Access

Understanding new PCSK9 outcome data: from the LDL-C hypothesis to LDL-c causality.

Session: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition & cardiovascular outcomes: review of lipid targets and treatment strategies (EBAC Accredited)

Topic: Lipids

Speaker: Professor J. Chapman (Paris, FR)

Organised by Physicians' Academy for Cardiovascular Education, supported with an educational grant by Sanofi/Regeneron and Amgen

Event: ESC Congress 2017

Congress Presentation

Add to my library

About the speaker

Professor John Chapman

Pitie Salpetriere APHP University Hospital, Paris (France)

17 presentations

0 follower

4 more presentations in this session

Introduction - PCSK9 inhibition & cardiovascular outcomes: review of lipid targets and treatment strategies.

Speaker: Doctor M. Farnier (Dijon, FR)

PCSK9 inhibition across a wide spectrum of patients: for whom is it efficacious?

Speaker: Doctor G. Hovingh (Amsterdam, NL)

PCSK9 inhibition & CV events: review of recent and upcoming hard endpoint outcome trials.

Speaker: Professor P. Sever (London, GB)

Discussion - PCSK9 inhibition & cardiovascular outcomes: review of lipid targets and treatment strategies.

Speaker: Professor W. Koenig (Munich, DE) Doctor M. Farnier (Dijon, FR)

Access the full session

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition & cardiovascular outcomes: review of lipid targets and treatment strategies (EBAC Accredited)

Speakers: Professor J. Chapman, Doctor M. Farnier, Doctor G. Hovingh, Professor P. Sever, Professor W. Koenig...

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources